Presented at Molecular Medicine Tri-Conference 2017, this presentation provides insights into how flow cytometry data analysis can be more precise, reliable, and valuable. With an exponential growth in personalized medicine and in particular immuno-oncology, flow cytometry has become a key tool for drug developers.
Download this presentation to learn more about how IQVIA Laboratories is helping its customers effectively utilize flow cytometry services by offering the largest global footprint for flow cytometry services, innovative technology that provides high quality data with minimal variability, and continuous improvement efficiency initiatives to meet customers' individual needs.
Author:
Mark Edinger, Scientific Advisor, Flow Cytometry
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Hybrid Assays for Protein Bioanalysis
Assays and Why Are They Essential for Protein Bioanalysis?
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
High Throughput ADME Testing
Minimizing turnaround time for ADME assays
ADME Services
Accelerating your drug discovery, preclinical and clinical programs with ADME services
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
Early Hit-to-Lead ADME Screening Bundle
Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
High Throughput ADME Screening Services
Capabilities that accelerate preclinical studies
IND-Enabling Bundle of In Vitro Assays to Assess Drug-Drug Interaction Risk
DDI Fact Sheet
